DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Albinterferon

Albinterferon

  • Current Therapies for Chronic Hepatitis C

    Current Therapies for Chronic Hepatitis C

  • Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation

    Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation

  • 7 Engineering of Therapeutic Proteins

    7 Engineering of Therapeutic Proteins

  • Part One General Information

    Part One General Information

  • Interferon in Inflammatory Diseases

    Interferon in Inflammatory Diseases

  • Translational Genomics, Transcriptomics and Metabolomics Analyses of the Metabolic Effects of Chronic Hepatitis C Infection and Their Clinical Implications

    Translational Genomics, Transcriptomics and Metabolomics Analyses of the Metabolic Effects of Chronic Hepatitis C Infection and Their Clinical Implications

  • (INN) for Biological and Biotechnological Substances

    (INN) for Biological and Biotechnological Substances

  • A Potent in Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon

    A Potent in Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon

  • Randomized Trial of Albinterferon Alfa2b Every 4Weeks for Chronic

    Randomized Trial of Albinterferon Alfa2b Every 4Weeks for Chronic

  • International Nonproprietary Names (INN) for Biological and Biotechnological Substances

    International Nonproprietary Names (INN) for Biological and Biotechnological Substances

  • Statistical Analysis Plan P15-698

    Statistical Analysis Plan P15-698

  • Dysregulation of Innate Immunity in Hepatitis C Virus Genotype 1 IL28B-Unfavorable Genotype Patients: Impaired Viral Kinetics and Therapeutic Response

    Dysregulation of Innate Immunity in Hepatitis C Virus Genotype 1 IL28B-Unfavorable Genotype Patients: Impaired Viral Kinetics and Therapeutic Response

  • Molecular Engineering of Therapeutic Cytokines

    Molecular Engineering of Therapeutic Cytokines

  • Withdrawal of the Marketing Authorisation Application for Joulferon (Albinterferon Alfa-2B)

    Withdrawal of the Marketing Authorisation Application for Joulferon (Albinterferon Alfa-2B)

  • Human Genome Sciences 2008 Annual Report

    Human Genome Sciences 2008 Annual Report

  • Interferon in Inflammatory Diseases

    Interferon in Inflammatory Diseases

  • Assessing the History and Value of Human Genome Sciences Received: May 23, 2013

    Assessing the History and Value of Human Genome Sciences Received: May 23, 2013

  • Immune-Modulators to Combat Hepatitis B Virus Infection: From

    Immune-Modulators to Combat Hepatitis B Virus Infection: From

Top View
  • Overview of Interferon: Characteristics, Signaling and Anti
  • The Way Forward in HCV Treatment — Finding the Right Path
  • Current and Future Treatment Options for HCV
  • The Future Use of Interferon in the Treatment of Hepatitis C: New Formulations, New Combinations
  • Us 2018 / 0271910 A1
  • WO 2015/153102 Al 8 October 2015 (08.10.2015) P O P C T
  • (INN) for Biological and Biotechnological Substances
  • Interferons As Therapeutic Agents in Infectious Diseases Mckenzie C
  • Large-Scale Production of Functional Human Serum Albumin from Transgenic Rice Seeds
  • Albinterferon Alfa-2B (Joulferon) for Hepatitis C with Compensated Liver Disease
  • Efficacy and Safety of a Novel Pegylated Interferon Alpha-2A in Egyptian Patients with Genotype 4 Chronic Hepatitis C
  • The Yin and Yang of Type I Ifns in Cancer Promotion and Immune Activation
  • Serum Albumin As a Local Therapeutic Agent in Cell Therapy and Tissue


© 2024 Docslib.org    Feedback